These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 22307435

  • 1. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
    Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S.
    Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
    [Abstract] [Full Text] [Related]

  • 2. Feasibility study of personalized peptide vaccination for advanced non-small cell lung cancer patients who failed two or more treatment regimens.
    Yamada T, Terazaki Y, Sakamoto S, Yoshiyama K, Matsueda S, Komatsu N, Waki K, Yamada A, Kawahara A, Kage M, Sugawara S, Yamashita Y, Sasada T, Takamori S, Itoh K.
    Int J Oncol; 2015 Jan; 46(1):55-62. PubMed ID: 25310280
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The impact of extent and location of mediastinal lymph node involvement on survival in Stage III non-small cell lung cancer patients treated with definitive radiotherapy.
    Fernandes AT, Mitra N, Xanthopoulos E, Evans T, Stevenson J, Langer C, Kucharczuk JC, Lin L, Rengan R.
    Int J Radiat Oncol Biol Phys; 2012 May 01; 83(1):340-7. PubMed ID: 22104359
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
    Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S.
    Clin Cancer Res; 2011 Nov 01; 17(21):6847-57. PubMed ID: 21918169
    [Abstract] [Full Text] [Related]

  • 13. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
    Hou X, Li Y, Luo RZ, Fu JH, He JH, Zhang LJ, Yang HX.
    Eur J Surg Oncol; 2012 Jun 01; 38(6):523-30. PubMed ID: 22440742
    [Abstract] [Full Text] [Related]

  • 14. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
    Pfannschmidt J, Muley T, Hoffmann H, Bülzebruck H, Dienemann H.
    Dtsch Med Wochenschr; 2006 Nov 24; 131(47):2643-8. PubMed ID: 17109272
    [Abstract] [Full Text] [Related]

  • 15. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
    Wakelee HA, Bernardo P, Johnson DH, Schiller JH.
    Cancer; 2006 May 15; 106(10):2208-17. PubMed ID: 16604529
    [Abstract] [Full Text] [Related]

  • 16. Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy.
    Cai XW, Xu LY, Wang L, Hayman JA, Chang AC, Pickens A, Cease KB, Orringer MB, Kong FM.
    Int J Radiat Oncol Biol Phys; 2010 Mar 15; 76(4):1100-5. PubMed ID: 19540063
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A, Fohlin H, Sörenson S.
    J Thorac Oncol; 2009 Mar 15; 4(3):326-32. PubMed ID: 19155996
    [Abstract] [Full Text] [Related]

  • 19. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
    Kawai O, Ishii G, Kubota K, Murata Y, Naito Y, Mizuno T, Aokage K, Saijo N, Nishiwaki Y, Gemma A, Kudoh S, Ochiai A.
    Cancer; 2008 Sep 15; 113(6):1387-95. PubMed ID: 18671239
    [Abstract] [Full Text] [Related]

  • 20. Prognostic factors in stage III non-small-cell lung cancer.
    Ademuyiwa FO, Johnson CS, White AS, Breen TE, Harvey J, Neubauer M, Hanna NH.
    Clin Lung Cancer; 2007 Sep 15; 8(8):478-82. PubMed ID: 17922971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.